Agreement provides Incyte the rights to develop and commercialize ENHANZE ® with its mutCALR development program and an option to nominate up to two additional targets
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio Both INCB161734, an investigational,...
/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte is scheduled to release its second-quarter results later this month, with analysts projecting a double-digit increase in its bottom line figure.
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?
- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) ...
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press...
Acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte’s late-stage pipeline
1 Mid-Cap Stock to Research Further and 2 We Avoid
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down